The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Open accessAbstract
Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic strategy but the mechanisms governing this process are poorly understood. Blockade of ERK1/2 reactivation following EGFR TKI treatment by combined EGFR/MEK inhibition uncovers cells that survive by entering a senescence-like dormant state characterized by high YAP/TEAD activity. YAP/TEAD engage the epithelial-to-mesenchymal transition transcription factor SLUG to directly repress pro-apoptotic BMF, limiting drug-induced apoptosis. Pharmacological co-inhibition of YAP and TEAD, or genetic deletion of YAP1, all deplete dormant cells by enhancing EGFR/MEK inhibition-induced apoptosis. Enhancing the initial efficacy of targeted therapies could ultimately lead to prolonged treatment responses in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Particularly, YAP/TAZ plays a crucial role in the intrinsic and acquired resistance to inhibitors targeting RTK/MAPK pathway (24, 28–32).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“accumulating evidence suggests that the dysregulation of the Hippo-YAP/TAZ pathway serves as a central resistance mechanism in multiple therapies, particularly in the intrinsic and acquired resistance to RTK, RAF, or MEK inhibitors (24, 28, 29).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“the authors observed that after treatment with the combination of EGFR and MEK inhibitors, the vast majority of barcodes were unique, suggesting that the ability of cells to enter dormancy following dual inhibition of EGFR and MEK is predominately driven by a stochastic process [56].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
In the citing paper
“The results revealed a large fraction of shared barcodes within the cells treated with EGFR inhibitor alone, consistent with selection of pre-existing persister clones.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
In the citing paper
“Meanwhile, other studies suggest that some persister phenotypes arise via plasticity induced by drug treatment [56,64,65].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
In the citing paper
“Kurppa et al. observed that combined EGFR/MEK inhibition of EGFR-mutant NSCLC model cells selected a population of dormant drug-tolerant cells exhibiting senescence-like features characterized by high YAP/TEAD activity [56].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096
Scenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 477
Abramson, Z. R., Dayton, O. L., Drane, W. E., Mendenhall, W. M., & Kaye, F. J. (2022) · Oral Oncology · doi:10.1016/j.oraloncology.2022.105854 · Cited by 18
Cai, S., Hu, T., Venkataraman, A., Moctezuma, F. G. R., Ozturk, E., Zhang, N. Y., Wang, M., Zvidzai, T., Das, S., Pillai, A. B., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01271-x · Cited by 18
Zhou, W., Liu, M., Li, X., Zhang, P., Li, J., Zhao, Y., Sun, G., & Mao, W. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00508-x · Cited by 18
Tanimura, K., Yamada, T., Horinaka, M., Katayama, Y., Fukui, S., Morimoto, K., Nakano, T., Tokuda, S., Morimoto, Y., Iwasaku, M., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.018 · Cited by 18
RBMS2 Chemosensitizes Breast Cancer Cells to Doxorubicin by Regulating BMF Expression
Xu, F., Xia, T., Xu, Q., Zhang, X., Huang, Y., Sun, X., Shi, L., Zhou, S., Wei, J., & Ding, Q. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66480 · Cited by 18
Early tolerance and late persistence as alternative drug responses in cancer
Punzi, S., Cittaro, D., Gatti, G., Crupi, G., Botrugno, O. A., Cartalemi, A. A., Gutfreund, A., Oneto, C., Giansanti, V., Battistini, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54728-7 · Cited by 18
Feng, Y., Gan, X., Rong, X., & Han, Q. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03946-0 · Cited by 19
Decoding the adaptive survival mechanisms of breast cancer dormancy
Barnieh, F. M., MORTON, J. K., Olanrewaju, O., & El‐Khamisy, S. F. (2025) · Oncogene · doi:10.1038/s41388-025-03529-3 · Cited by 18
Hippo in Gastric Cancer: From Signalling to Therapy
Seeneevassen, L., Dubus, P. R., Gronnier, C., & Varon, C. (2022) · Cancers · doi:10.3390/cancers14092282 · Cited by 18
Sun, S. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2022.10.001 · Cited by 20
Persisting cancer cells are different from bacterial persisters
Decollogny, M., & Rottenberg, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.002 · Cited by 16
Graham, K., Lienau, P., Bader, B., Prechtl, S., Naujoks, J., Lesche, R., Weiske, J., Kuehnlenz, J., Brzezinka, K., Potze, L., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.02.013 · Cited by 16
Izumi, M., Costa, D. B., & Kobayashi, S. S. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107885 · Cited by 20
Yoo, G., Park, D., Kim, Y., & Chung, C. (2021) · Cancers · doi:10.3390/cancers13123069 · Cited by 17
Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies
Yang, S., Seo, J., Choi, J., Kim, S.-H., Kuk, Y., Park, K. C., Kang, M., Byun, S., & Joo, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02250-9 · Cited by 20
Self-citationTEAD-targeting small molecules induce a cofactor switch to regulate the Hippo pathway
Guarnaccia, A. D., Hagenbeek, T. J., Lee, W., Kljavin, N. M., Choi, M., Tombling, B. J., Peukert, C., Ulas, G., Kameswaran, V., Le, D., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425984122 · Cited by 17
Li, H., Xu, W., Cheng, W., Yu, G., & Tang, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1612089 · Cited by 17
Cancer dormancy and metabolism: From molecular insights to translational opportunities
Wang, Y., Liu, L., Zhang, X., Liang, T., & Bai, X. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218097 · Cited by 19
Shimizu, Y., Okada, K., Adachi, J., Abe, Y., Narumi, R., Uchibori, K., Yanagitani, N., Koike, S., Takagi, S., Nishio, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00260-0 · Cited by 16
Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors
Dieter, S. M., Lovecchio, D., Pataskar, A., Zowada, M. K., Körner, P.-R., Khalizieva, A., van Tellingen, O., Jäger, D., Glimm, H., & Agami, R. (2022) · Oncogene · doi:10.1038/s41388-022-02400-z · Cited by 16
Conquering oncogenic KRAS and its bypass mechanisms
Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 18
Fnaiche, A., Chan, H., Paquin, A., Suárez, N. G., Vu, V., Li, F., Allali‐Hassani, A., Cao, M. A., Szewczyk, M. M., Bolotokova, A., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00386 · Cited by 16
Theard, P. L., Linke, A. J., Sealover, N. E., Daley, B. R., Yang, J. J., Cox, K., & Kortum, R. L. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13564 · Cited by 17
Unveiling the role of cellular dormancy in cancer progression and recurrence
Collignon, É. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001013 · Cited by 16
Effect of illuminance and colour temperature of LED lighting on asthenopia during reading
Chen, Y., Ma, T., Ye, Z., & Li, Z. (2022) · Ophthalmic and Physiological Optics · doi:10.1111/opo.13051 · Cited by 16
Song, T., Yao, M., Yang, Y., Liu, Z., Zhang, L., & Li, W. (2023) · Phenomics · doi:10.1007/s43657-023-00103-3 · Cited by 17
Identification of a Gene Signature That Predicts Dependence upon YAP/TAZ-TEAD
Kanai, R., Norton, E., Stern, P., Hynes, R. O., & Lamar, J. M. (2024) · Cancers · doi:10.3390/cancers16050852 · Cited by 16
Loi, P., Schade, A. E., Rodriguez, C. L., Krishnan, A., Perurena, N., Nguyen, V. T. M., Xu, Y., Watanabe, M., Davis, R. A., Gardner, A., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0866 · Cited by 19
Xu, Q., Wen, X., Huang, C., Lin, Z., Xu, Z., Sun, C., Li, L., Zhang, S., Song, S., Lou, J., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002099 · Cited by 16
Advances in Palmitoylation: A key Regulator of liver cancer development and therapeutic targets
Zhu, Z., Feng, S., Zeng, A., & Song, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116810 · Cited by 15
Senesce to Survive: YAP-Mediated Dormancy Escapes EGFR/MEK Inhibition
Bado, I. L., & Zhang, X. H.-F. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.008 · Cited by 15
Yanagimura, N., Takeuchi, S., Fukuda, K., Arai, S., Tanimoto, A., Nishiyama, A., Ogo, N., Takahashi, H., Asai, A., Watanabe, S., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00254-y · Cited by 16
Persister cells that survive chemotherapy are pinpointed
Rehman, S. K., & O'Brien, C. A. (2022) · Nature · doi:10.1038/d41586-022-01866-x · Cited by 15
In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies
Sealover, N. E., Theard, P. L., Hughes, J. M., Linke, A. J., Daley, B. R., & Kortum, R. L. (2023) · iScience · doi:10.1016/j.isci.2023.108711 · Cited by 14
Good Guy in Bad Company: How STRNs Convert PP2A into an Oncoprotein
Kurppa, K. J., & Westermarck, J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.011 · Cited by 12
Self-citationInsights into auto- S -fatty acylation: targets, druggability, and inhibitors
Hu, L., Tao, Z., & Wu, X. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00115a · Cited by 15
Mechanism and application of feedback loops formed by mechanotransduction and histone modifications
Sun, H., Gao, Y., Ma, X., Deng, Y., Bi, L., & Li, L. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.030 · Cited by 15
Self-citationYAP at the Crossroads of Biomechanics and Drug Resistance in Human Cancer
Huang, M. L., Wang, H., Mackey, C., Chung, M. C., Guan, J., Zheng, G., Roy, A., Xie, M., Vulpe, C. D., & Tang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512491 · Cited by 14
Self-citationMa, D., Luo, Q., & Song, G. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.213936 · Cited by 16
Li, J., Wang, X., Zhang, H., Hu, X., Peng, X., Jiang, W., Zhuo, L., Peng, Y., Zeng, G., & Wang, Z. (2024) · Medicinal Research Reviews · doi:10.1002/med.22079 · Cited by 16
Gong, K., Guo, G., Beckley, N. A., Yang, X., Zhang, Y., Gerber, D. E., Minna, J. D., Burma, S., Zhao, D., Akbay, E. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27276-7 · Cited by 15
The epigenome and the many facets of cancer drug tolerance
Moore, P. C., Henderson, K. W., & Classon, M. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.002 · Cited by 14
Tiedt, R., King, F. J., Stamm, C., Niederst, M. J., Delach, S. M., Zumstein-Mecker, S., Meltzer, J., Mulford, I. J., Labrot, E., Engstler, B. S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112297 · Cited by 13
Kumar, S., Gahramanov, V., Patel, S. H., Yaglom, J. A., Kaczmarczyk, L. S., Alexandrov, I. A., Gerlitz, G., Salmon‐Divon, M., & Sherman, M. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108717 · Cited by 13
Critical functions of extracellular matrix in brain metastasis seeding
Yuzhalin, A. E., & Yu, D. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04944-z · Cited by 15
Fnaiche, A., Mélin, L., Suárez, N. G., Paquin, A., Vu, V., Li, F., Allali‐Hassani, A., Bolotokova, A., Allemand, F., Gelin, M., et al. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129488 · Cited by 13
Popescu, B. O., Stahlhut, C. E., Tarver, T. C., Wishner, S., Lee, B. J., Peretz, C. A. C., Luck, C., Phojanakong, P. J., Cámara, J. A., Hongo, H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101290 · Cited by 12
Pan-Transcriptional Enhanced Associated Domain Palmitoylation Pocket Covalent Inhibitor
Kim, J. S., Kim, H., Kim, J., Cho, S. Y., Moon, S., Yoo, Y., Kim, H., Kim, J., Jeon, H., Namkung, W., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01393 · Cited by 13
The recent advances and implications in cancer therapy for the hippo pathway
Chan, S. W., Ong, C., & Hong, W. (2025) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2025.102476 · Cited by 13
Advances in the activity of resveratrol and its derivatives in cardiovascular diseases
Peng, Y., Zheng, X., Zhang, S., Luo, Z., Li, S., Chen, H., & Yao, X. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400865 · Cited by 13
Self-citationTargeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance
Roberts, S. K., Galgadas, I., Clarke, D. T., Zanetti-Domingues, L. C., Gervasio, F. L., & Martin-Fernandez, M. L. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104407 · Cited by 14
Epigenetic adaptations in drug-tolerant tumor cells
Mani, N., Daiya, A., Chowdhury, R., Mukherjee, S., & Chowdhury, S. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.006 · Cited by 13
The Mechanical Role of YAP/TAZ in the Development of Diabetic Cardiomyopathy
Shen, J.-X., Zhang, L., Liu, H., Zhang, Z., Zhao, N., Zhou, J., Qian, L., & Wang, R. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050297 · Cited by 12
A covalent inhibitor of the YAP–TEAD transcriptional complex identified by high-throughput screening
Nutsch, K., Song, L., Chen, E., Hull, M. V., Chatterjee, A. K., Chen, J. J., & Bollong, M. J. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00044c · Cited by 11
The complex journey of targeting RAS in oncology
Wasiak, K., Ciunowicz, D., Kierasińska, A., Węgierska, M., Pacholczyk, M., Rieske, P., & Stoczyńska-Fidelus, E. (2025) · BMC Cancer · doi:10.1186/s12885-025-14033-y · Cited by 14
Synthetic molecules targeting yes associated protein activity as chemotherapeutics against cancer
Iftikhar, R., Zahoor, A. F., Irfan, M., Rasul, A., & Rao, F. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13960 · Cited by 12
The Hippo pathway: a renewed insight in the craniofacial diseases and hard tissue remodeling
Chen, J., Cheng, J., Zhao, C., Zhao, B., Mi, J., & Li, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.63305 · Cited by 13
Opposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinomaPreprint
Fort, G., Arnold, H., Camolotto, S. A., O’Toole, K. T., Tariq, R., Waters, A. K., Gillis, K., & Snyder, E. L. (2025) · Genes & Development · doi:10.1101/gad.352742.125 · Cited by 13
Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling
Oh, H., Hwang, I., Jang, J.-Y., Wu, L., Cao, D., Yao, J., Ying, H., Li, J. Y., Yao, Y., Hu, B., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1810 · Cited by 11
Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors
Sun, S. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0951-0 · Cited by 11
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
Meraz, I. M., Majidi, M., Fang, B., Meng, F., Gao, L., Shao, R., Song, R., Li, F., Lissanu, Y., Chen, H., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04889-w · Cited by 11
Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Cotton, J. L., Estrada, J., Sagar, V., Chen, J. T., Piquet, M., Alford, J., Song, Y., Li, X., Riester, M., DiMare, M. T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0144 · Cited by 12
Ogimoto, T., Ozasa, H., Tsuji, T., Funazo, T. Y., Yamazoe, M., Hashimoto, K., Yoshida, H., Hosoya, K., Ajimizu, H., Nomizo, T., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0371 · Cited by 11
Strategies that regulate Hippo signaling pathway for novel anticancer therapeutics
Li, N., Liu, Y., Wu, J. Y., Liu, Q.-G., Niu, J.-B., Zhang, Y., Fu, X.-J., Song, J. H., & Zhang, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116694 · Cited by 11
Self-citationThe Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer
Zhong, B., Du, J., Liu, F., & Sun, S. (2025) · MedComm · doi:10.1002/mco2.70128 · Cited by 10
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Bersani, F., Morena, D., Picca, F., Morotti, A., Tabbò, F., Bironzo, P., Righi, L., & Taulli, R. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-189 · Cited by 10
RAS and PP2A activities converge on epigenetic gene regulation
Aakula, A., Sharma, M., Tabaro, F., Nätkin, R., Kamila, J., Honkanen, H., Schapira, M., Arrowsmith, C. H., Nykter, M., & Westermarck, J. K. (2023) · Life Science Alliance · doi:10.26508/lsa.202301928 · Cited by 12
Li, S., Zhang, Y., Luo, M., Zhou, W., Chen, Y., Wu, D., Wei, Q., Chang, Y., & Hu, H. (2025) · Cell Discovery · doi:10.1038/s41421-025-00817-w · Cited by 12
Self-citationHsu, H.-E., Martin, M. J., Weng, S.-H., Kitata, R. B., Nagelli, S. G., Chang, C., Hess, S. Y., & Chen, Y. (2025) · Molecular Systems Biology · doi:10.1038/s44320-025-00141-1 · Cited by 10
Qian, L., Vallega, K. A., Yao, W., Wang, D., Zhai, Y., He, X., & Sun, S. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23458 · Cited by 11
Exosomal microRNA Therapy for Non-Small-Cell Lung Cancer
Chen, J., Wu, F., Hou, E., Zeng, J., Li, F., & Gao, H. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231210731 · Cited by 10
Evsen, L., Morris, P. J., Thomas, C. J., & Ceribelli, M. (2023) · Pharmaceuticals · doi:10.3390/ph16121635 · Cited by 10
KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance
Chatterjee, D., Svoboda, R. A., Huisman, D. H., Drapkin, B. J., Vieira, H. M., Rao, C., Askew, J. W., Fisher, K. W., & Lewis, R. E. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0652 · Cited by 10
Deng, Y.-R., Wu, Q.-Z., Zhang, W., Jiang, H., Xu, C.-Q., Chen, S., Fan, J., Guo, S., & Chen, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06350-4 · Cited by 10
TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression
Wang, C., Zhang, S., Ma, B., Fu, Y., & Luo, Y. (2022) · Oncogene · doi:10.1038/s41388-022-02260-7 · Cited by 10
A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment
Shim, J., & Goldsmith, K. C. (2021) · Cancers · doi:10.3390/cancers13184650 · Cited by 10
RAS-mediated tumor stress adaptation and the targeting opportunities it presents
Redding, A., Aplin, A. E., & Grabocka, E. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049280 · Cited by 11
The molecular mechanisms of chemotherapeutic resistance in tumors (Review)
Weng, X., Zeng, W.-H., Zhong, L., Xie, L., Ge, W.-J., Lai, Z., Qin, Q., Liu, P., Cao, D., & Zeng, X. (2024) · Oncology Reports · doi:10.3892/or.2024.8816 · Cited by 9
YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Katayama, Y., Yamada, T., Tanimura, K., Kawachi, H., Ishida, M., Matsui, Y., Hirai, S., Nakamura, R., Morimoto, K., Furuya, N., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1762 · Cited by 9
Shi, R., Farnsworth, D., Febres‐Aldana, C. A., Chow, J. L. M., Sheena, R., Atwal, T., Marti, J. L. G., Li, S., Thomas, K. N., Lee, C.-M., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03461-6 · Cited by 13
Self-citationBcl-2 modifying factor (Bmf): “a mysterious stranger” in the Bcl-2 family proteins
Pervushin, N. V., Nilov, D. K., Zhivotovsky, B., & Kopeina, G. S. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01562-z · Cited by 9
Zhang, X., Wen, Y., Wu, F., Jiang, Y., Lin, Y., Wang, L., Zhou, F., Shen, Y., Min, Z., Li, W., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.10.001 · Cited by 10
[Lung Cancer Stem-like Cells and Drug Resistance].
Pan, Z., Liu, H., & Chen, J. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.02 · Cited by 9
Hao, F. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02826-7 · Cited by 10
Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro
Pettitt, G. A., Hurst, C. D., Khan, Z., McPherson, H. R., Dunning, M. C., Alder, O., Platt, F. M., Black, E. V. I., Burns, J. E., & Knowles, M. A. (2022) · The Journal of Pathology · doi:10.1002/path.6034 · Cited by 10
Metastasis prevention: How to catch metastatic seeds
Gerashchenko, T. S., Schegoleva, A. A., Khozyainova, A. A., Чойнзонов, Е. Л., & Denisov, E. V. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188867 · Cited by 9
Novel Allosteric Effectors Targeting Human Transcription Factor TEAD
Ibrahim, M. T., Verkhivker, G. M., Misra, J. R., & Tao, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109009 · Cited by 9
Cellular Self-Digestion and Persistence in Bacteria
Mohiuddin, S. G., Ghosh, S., Ngo, H. G., Sensenbach, S., Karki, P., Dewangan, N. K., Angardi, V., & Orman, M. A. (2021) · Microorganisms · doi:10.3390/microorganisms9112269 · Cited by 10
Zhao, B., Tang, M., & Lv, Y. (2022) · Human Cell · doi:10.1007/s13577-021-00666-1 · Cited by 9
Martin, M. J., Floc’h, N., Pfeifer, M., Criscione, S. W., Delpuech, O., Gagrica, S., Yao, Y., McDermott, U., & Smith, P. D. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0066 · Cited by 9
Tian, Z., You, Y., Meng, X., Liu, J., Xu, G., Ma, C., Du, Z., & Wang, Y. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.78386 · Cited by 11
Lailler, C., Didelot, A., Garinet, S., Berthou, H., Sroussi, M., de Reyniès, A., Dedhar, S., Martin‐Lannerée, S., Fabre, E., Pimpec‐Barthes, F. L., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03130-0 · Cited by 9
Dong, C., Liu, Y., Chong, S., Zeng, J., Bian, Z., Chen, X., & Fan, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179502 · Cited by 8
Self-citationPKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
Killarney, S. T., Mesa, G., Washart, R., Mayro, B., Dillon, K. A., Wardell, S. E., Newlin, M., Lu, M., Rmaileh, A. A., Liu, N., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0928 · Cited by 9
Nangia, V., Ashraf, H. M., Marikar, N. C., Passanisi, V. J., Christopher, R., & Spencer, S. L. (2025) · Science Signaling · doi:10.1126/scisignal.adw3231 · Cited by 11
Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity
Cao, L., Yang, J., Liu, Y., Chen, X., Shi, Y., Zhao, Y., Zhang, Y., Chen, J., Li, B., Wen, W., et al. (2025) · Advanced Science · doi:10.1002/advs.202503277 · Cited by 8
Self-citationAndo, T., Okamoto, K., Shintani, T., Yanamoto, S., Miyauchi, M., Gutkind, J. S., & Kajiya, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101544 · Cited by 8
Dolan, M., Shi, Y., Mastri, M., Long, M. D., McKenery, A., Hill, J. W., Vaghi, C., Benzekry, S., Barbi, J. J., & Ebos, J. M. L. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0139 · Cited by 7
Yang, L., Gan, Y., Deng, H., He, J., & Xu, X. (2024) · Reviews in Aquaculture · doi:10.1111/raq.12955 · Cited by 7
Alva‐Ruiz, R., Watkins, R. D., Tomlinson, J. L., Yonkus, J. A., Abdelrahman, A. M., Conboy, C. B., Jessen, E., Werneburg, N. W., Kuipers, H., Sample, J. W., et al. (2024) · FEBS Open Bio · doi:10.1002/2211-5463.13901 · Cited by 7
Metadata
- Authors
- Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., Portell, A., Lizotte, P. H., Ficarro, S. B., Li, S., Chen, T., Haikala, H. M., Wang, H., Bahcall, M., Gao, Y., Shalhout, S., Boettcher, S., Shin, B. H., Thai, T., Wilkens, M. K., Tillgren, M. L., Mushajiang, M., Xu, M., Choi, J., Bertram, A. A., Ebert, B. L., Beroukhim, R., Bandopadhayay, P., Awad, M. M., Gokhale, P. C., Kirschmeier, P. T., Marto, J. A., Camargo, F. D., Haq, R., Paweletz, C. P., Wong, K.-K., Barbie, D. A., Long, H. W., Gray, N. S., & Jänne, P. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- NYU Langone Health (US)
- Tongji University (CN)
- Boston Children's Hospital (US)
- Broad Institute (US)
- ORCID
- Kurppa, Kari J.
- Liu, Yao
- To, Ciric
- Zhang, Tinghu
- Fan, Mengyang
- Vajdi, Amir
- Knelson, Erik H.
- Xie, Yingtian
- Lim, Klothilda
- Cejas, Paloma
- Portell, Andrew
- Lizotte, Patrick H.
- Ficarro, Scott B.
- Li, Shuai
- Chen, Ting
- Haikala, Heidi M.
- Wang, Haiyun
- Bahcall, Magda
- Gao, Yang
- Shalhout, Sophia
- Boettcher, Steffen
- Shin, Bo Hee
- Thai, Tran
- Wilkens, Margaret K.
- Xu, Man
- Choi, Jihyun
- Bertram, Arrien A.
- Ebert, Benjamin L.
- Beroukhim, Rameen
- Bandopadhayay, Pratiti
- Awad, Mark M.
- Gokhale, Prafulla C.
- Marto, Jarrod A.
- Camargo, Fernando D.
- Haq, Rizwan
- Paweletz, Cloud P.
- Wong, Kwok-Kin
- Barbie, David A.
- Long, Henry W.
- Gray, Nathanael S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 37
- Issue
- 1
- Pages
- 104-122.e12
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC7146079
- OpenAlex
- W3000285141
- Cited by
- 475
- References
- 92
- Citations by year
- 2026: 50 · 2025: 94 · 2024: 82 · 2023: 81 · 2022: 71 · 2021: 65 · 2020: 30
- FWCI
- 30.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UTUPub (University of Turku) (submittedVersion)
- Funders
- National Cancer Institute (NIH 5 P30 CA06516, R01CA135257, R35CA220497)
- Novartis Institutes for BioMedical Research
- Bristol-Myers Squibb
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Eli Lilly and Company
- Daiichi Sankyo Company
- Astellas Pharma US
- Dana-Farber/Harvard Cancer Center
- American Cancer Society (CRP-17-111-01-CDD)
- Takeda Oncology
- Massachusetts Institute of Technology
- Instrumentariumin Tiedesäätiö
- Takeda Pharmaceuticals U.S.A.
- National Science Foundation (P300PB_161026/1, P400PM_183862)
- Dana-Farber Cancer Institute
- National Institutes of Health (CA233800, R01 CA222218)
- Jane ja Aatos Erkon Säätiö
- Novartis
- Krebsliga Schweiz (KLS-3625-02 2015)
- Sanofi
- Orionin Tutkimussäätiö
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- tumor dormancy, EGFR tyrosine kinase inhibitors, EGFR-mutant non-small cell lung cancer, MEK inhibition, Slug, BMF, apoptosis, transcriptional reprogramming, drug resistance
- MeSH terms
- YAP-Signaling Proteins, Animals, Cell Survival, Female, Humans, Lung Neoplasms, Male, Mutation, Transcription Factors, Transcription, Genetic, Signal Transduction, Gene Expression Regulation, Neoplastic, Cellular Senescence, Apoptosis, Gene Deletion, Mice, Knockout, Cell Cycle Proteins, Drug Resistance, Neoplasm, Cell Line, Tumor, MAP Kinase Kinase 1, Adaptor Proteins, Signal Transducing, Cell Proliferation, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
